Abstract:Background: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has a well-characterized efficacy and safety profile in patients with hypertension. AZL-M is approved for use in over 40 countries globally; however, it is not yet approved in China. Therefore, a phase 3 registration study to assess the efficacy (antihypertensive effect), safety, and tolerability of AZL-M compared with valsartan in Chinese patients with essential hypertension was undertaken. Methods: This multicenter, double-blind, randomized, 8-week phase 3 study compared AZL-M with valsartan in Chinese patients aged >= 18 years with essential hypertension. Endpoints included change from baseline to week 8 in trough sitting clinic systolic blood pressure (scSBP) and ambulatory blood pressure monitoring parameters. Results: Overall, 612 patients (mean age, 57.1 years; 57.5% male) were randomized to AZL-M 80 mg (n = 209), AZL-M 40 mg (n = 199), or valsartan 160 mg (n = 204). Baseline mean scSBP was similar in all groups (157.9-158.5 mm Hg). The mean reduction in trough scSBP from baseline to week 8 was significantly greater with AZL-M 80 mg than with valsartan (-24.2 vs -20.6 mm Hg;P = .010), and noninferior with AZL-M 40 mg versus valsartan (-22.5 vs -20.6 mm Hg;P = .184). Mean reduction in 24-hour mean systolic blood pressure (n = 257) was significantly greater with both AZL-M 80 mg (-17.0 mm Hg;P < .001) and AZL-M 40 mg (-14.7 mm Hg;P = .014) than with valsartan (-9.4 mm Hg). Treatment-emergent adverse events had similar incidence (52.8%-56.5%) across the treatment groups and were generally mild or moderate. Dizziness was the most frequent treatment-related treatment-emergent adverse events (AZL-M 80 mg, 1.9%; AZL-M 40 mg, 1.5%; valsartan, 1.0%). The safety and tolerability of AZL-M were comparable with valsartan. Conclusions: AZL-M was noninferior to valsartan at the 40-mg dose and superior to valsartan at the 80-mg dose in reducing trough scSBP, and showed acceptable safety-consistent with the AZL-M safety profile in other populations-in Chinese adults with hypertension.

Efficacy and Safety of Olmesartan Medoxomil‑amlodipine Besylate Tablets (sevikar®) in Older Patients with Essential Hypertension: Subgroup Analysis from the Sevikar Study.

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Clinical Study of Olmesartan/hydrochlorothiazide Compound Tablet in Mild to Moderate Essential Hypertensive Patients Who Did Not Reach Goal with Olmesartan

Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared with Olmesartan in Elderly Asian Patients (≥65 Years) with Systolic Hypertension.

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy

Clinical Efficacy and Safety of Combination Therapy with Amlodipine and Olmesartan or an Olmesartan/Hydrochlorothiazide Compound for Hypertension: A Prospective, Open-Label, and Multicenter Clinical Trial in China.

Efficacy and Safety of Olmesartan Medoxomil in Patients with Mild to Moderate Essential Hypertension

Using Different Methods to Evaluate the Efficacy of Olmesartan Medoxomil in Chinese Patients with Mild to Moderate Essential Hypertension According to Ambulatory Blood Pressure Monitoring

Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study

G-002 AMLODIPINE/VALSARTAN 5/160 MG VERSUS VALSARTAN 160 MG IN PREDOMINANTLY CHINESE PATIENTS WITH STAGE 1 OR 2 ESSENTIAL HYPERTENSION NOT ADEQUATELY CONTROLLED ON VALSARTAN 160 MG MONOTHERAPY

Comparative Effectiveness of an Angiotensin Receptor Blocker, Olmesartan Medoxomil, in Older Hypertensive Patients

Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension

Efficacy and Safety of Sacubitril/valsartan Compared with Olmesartan in Asian Patients with Essential Hypertension: A Randomized, Double-Blind, 8-Week Study.

Long-Term Efficacy of Olmesartan Medoxomil in Chinese Hypertensive Patients As Assessed by Clinic, Ambulatory and Home Blood Pressure Measurements

The Effects of Olmesartan on Ambulatory Blood Pressures and Blood Pressure Variability in Patients with Mild to Moderate Essential Hypertension

Effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil tablet

China STudy of Valsartan/amlodipine Fixed-Dose Combination-Based Long-Term Blood Pressure Management in HypertenSive Patients: a One-Year Registry (china STATUS III)

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension

Efficacy of Olmesartan/Amlodipine Single‐Pill Combination on 24‐h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non‐Responders to Valsartan or Candesartan Monotherapy